During the past decade, Irkutsk Regional Oncology Dispensary conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Irkutsk Regional Oncology Dispensary" #1 sponsor was "Janssen Research & Development, LLC" with 3 trials, followed by "Merck Sharp & Dohme LLC" with 3 trials sponsored, "BeiGene" with 1 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored and "Jiangsu HengRui Medicine Co., Ltd." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Irkutsk Regional Oncology Dispensary" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "PPD" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Irkutsk Regional Oncology Dispensary" are "Prostatic Neoplasms" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "ALK+ Advanced NSCLC" (1 trials), "First Line Non-Small Cell Lung Cancer" (1 trials) and "Hepatocellular Carcinoma" (1 trials). Many other conditions were trialed in "Irkutsk Regional Oncology Dispensary" in a lesser frequency.

Most popular intervention types in "Irkutsk Regional Oncology Dispensary" are "Drug" (13 trials), "Biological" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (4 trials), "Docetaxel" (3 trials), "Placebo" (3 trials), "Amivantamab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Irkutsk Regional Oncology Dispensary" are 10 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Irkutsk Regional Oncology Dispensary". undefined are not yet recruiting, 1 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Irkutsk Regional Oncology Dispensary, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Irkutsk Regional Oncology Dispensary, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".